12:00 AM
Aug 19, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/16 cls
Amarin Corp. plc (NASDAQ:AMRN) H.C. Wainwright Andrew Fein Upgrade Buy (from neutral) 11% $6
Fein also raised his target to $10 from $6 ahead of an Oct. 16 FDA advisory committee meeting to discuss an sNDA for Vascepa icosapent ethyl to expand the drug's label to include treatment of adults with high triglycerides with mixed dyslipidemia. Vascepa is approved to treat adult...

Read the full 512 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >